Psoriasis, Psoriatic Arthritis, IL-23 and Skyrizi: Understanding Chronic Inflammation and Targeted Biological Therapy
The role of the IL-23/IL-17 inflammatory pathway in psoriasis, psoriatic arthritis and related immune-mediated diseases, and how Skyrizi (risankizumab) helps control chronic inflammation. Introduction: Chronic Inflammation as a Common Biological Link Psoriasis and psoriatic arthritis are systemic immune-mediated inflammatory diseases that extend beyond the skin and joints. Both involve dysregulation of the immune system, with inflammatory signaling molecules known as cytokines playing important roles in maintaining chronic inflammation. Among these cytokines, interleukin-23 (IL-23) and interleukin-17 (IL-17) are particularly important in the development and progression of psoriatic disease. The IL-23/IL-17 signaling pathway regulates immune-cell activity and inflammatory responses. When dysregulated, it contributes to persistent inflammation, tissue injury and structural changes in affected organs. The development of targeted biological therapies has significantly changed the treatment...